Ariela Katz

Princeton

Editor at Hematology Advisor

Featured in: Favicon

hematologyadvisor.com Favicon

onclive.com Favicon

curetoday.com Favicon

cancertherapyadvisor.com Favicon

psychiatryadvisor.com Favicon

renalandurologynews.com Favicon

oncologynurseadvisor.com Favicon

infectiousdiseaseadvisor.com Favicon

targetedonc.com Favicon

oncnursingnews.com + 2 more

Articles

Phase 3 Trials Explore Pirtobrutinib in CLL/SLL and MCL

Jul 21, 2023 | hematologyadvisor.com | Ariela Katz

The BTK inhibitor pirtobrutinib recently demonstrated efficacy in a phase 1/2 trial of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had previously received BTK inhibitor treatment.1Now, researchers are investigating pirtobrutinib in 4 ongoing phase 3 trials.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →